PEPINSKY, R., BLAKE,MI, SHA,SHAO, ZHAOHUI,GRAFF, CHRISTILYN, P.,PEPINSKY, R., Blake,MI, Sha,SHAO, Zhaohui,GRAFF, Christilyn, P.
申请号：
RSP20130520
公开号：
RS53058B
申请日:
2006.07.07
申请国别(地区):
RS
年份:
2014
代理人:
摘要：
Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination (Negative Regulator). Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-Sp35 antibody.Izolovano antitelo ili njegov antigen - vezujući fragment koji mogu specifično da sc vežu za Sp35 i koji mogu da antagonizuju Sp35, pri čemu su antitelo ili njegov fragment izabrani iz grupe koja se sastoji od:(i) antitela ili njegovog antigen - vezujućeg fragmenta koji se sadrži VH, pr čemu su CDRl, CDR2 i CDR3 regioni VH-a SEQ ID NO:77, SEQ ID NO:78 i SEQ ID NO:79, i VL, pri čemu su CDRl, CDR2 i CDR3 regioni VL-a SEQ ID NO:146, SEQ ID NO:147 i SEQ ID NO:148； i(ii) antitela ili njegovog antigen vezujućeg fragmenta koji sadrži VII i VL, pri čemu VH sadrži SEQ ID NO:170, a VL sadrži SEQ II) NO:283.Prijava sadrži još 8 patentnih zahteva.
